Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (noted as Lifecore Biomedical in metadata, but identified as Landec in the filing text) on June 5, 2008. The report details the dismissal of the independent registered public accounting firm, McGladrey & Pullen, LLP, and the subsequent engagement of Ernst & Young LLP (E&Y) to audit the fiscal year ending May 25, 2008.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It explicitly states that management expects no impact on the Company's cash position or the timing of cash receipts and disbursements previously reported.
Material Changes and Accounting Issues
The primary material change is the replacement of the auditor due to unresolved "Accounting Issues" and a perceived conflict of interest. McGladrey identified four specific areas of disagreement or concern:
- Revenue Recognition: Questions regarding the gain on the sale of Fielder's Choice Direct to Monsanto and revenue recognition for the Intellicoat licensing agreement.
- Equity vs. Asset Treatment: Whether the repurchase of subsidiary options (Apio, Inc. and Landec Ag, Inc.) should be recorded as an asset (purchase of minority interest) rather than a reduction to equity.
- Consolidation: Whether the Company is the primary beneficiary of Landec Ag, determining if it should be deconsolidated.
- Deferred Taxes: The level of detail required for deferred tax assets, liabilities, and valuation allowances in fiscal year 2007 footnotes.
McGladrey indicated that if their interpretation of these issues were deemed correct, they would seek fees for their evaluation, a position the Audit Committee viewed as a significant conflict of interest.
Outlook, Management Commentary, and Risks
Management Commentary: The Audit Committee concluded that the Company's accounting positions, which were previously approved by E&Y, are reasonable and consistent with generally accepted accounting principles. An independent expert consultant retained by the Committee agreed, finding McGladrey's stance inappropriate given the defensibility of the Company's position.
Rationale for Change: The switch to E&Y is intended to ensure a cost-effective and timely completion of the 2008 fiscal year audit. The Committee cited McGladrey's unsatisfactory service level, failure to communicate effectively, and the conflict of interest regarding potential fees as primary drivers for the dismissal.
Risks and Contingencies: The Company is preparing written submissions to the SEC's Office of the Chief Accountant to resolve the accounting issues. While the Company believes its filings are accurate, the existence of these disagreements represents a regulatory risk until formally resolved.
Investor Verification Checklist
- Verify the content of the letter from Ernst & Young LLP (Exhibit 16.1) confirming their agreement with the Company's accounting treatment.
- Monitor future SEC filings for the resolution of the four specific accounting issues with the Office of the Chief Accountant.
- Review the upcoming Form 10-K for the fiscal year ended May 25, 2008, to confirm no restatements are required regarding the sale of Fielder's Choice Direct or the subsidiary option repurchases.
- Assess the impact of the auditor change on the timeline for future quarterly and annual reporting.